Gameto

Gameto is a biotechnology startup focused on redefining female reproductive health through the development of cell therapies. The company's mission is to address the underserved therapeutic area of women's health by providing improved treatment options with fewer complications and greater clinical benefits.

Using cutting-edge scientific advances, Gameto has developed a platform for producing female reproductive cell lines through cellular engineering. These engineered ovarian and endometrium cell lines are designed to mimic the functions of endogenous cells, producing and responding to all hormones.

The company's main focus is on advancing a portfolio of cellular therapeutics for female reproductive diseases. Their first program, Fertilo, is a therapeutic for IVF and egg freezing, aiming to make the process shorter, safer, and more effective. Additionally, Gameto is working on an organoid of the female reproductive system, Deovo, and a cell-based therapeutic for the health consequences of primary ovarian insufficiency and menopause, Ameno.

Founded in 2020 and headquartered in the United States, Gameto recently secured a $17.00M Venture Round investment on 14 September 2022. The investment was led by Future Ventures, Gaingels, TA Ventures, Insight Partners, Plum Alley Investments, Bold Capital Partners, Arcadia Partners, Korify Capital, and Myelin Capital. With this substantial investment, Gameto is well-positioned to continue its pioneering work in female reproductive health.